Apheresis CD8⁺CCR7⁺CD45RA^- T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.

ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL); however, a significant proportion of patients fail to achieve a durable response, underscoring the need for reliable predictive biomarkers. We characterize T-lymphocyte subpopulations in apheresis samples from 23 r/r large B-cell lymphoma (LBCL) patients who received axicabtagene ciloleucel (axi-cel) to identify pre-treatment cell biomarkers associated with CAR T-cell kinetics and clinical outcomes. Immunophenotyping of T-cells within fresh apheresis samples and monitoring of circulating CAR T-cells were performed by multiparametric flow cytometry. The median peak CAR T-cell count was 45.2 CAR T-cells/mL. Strong CAR-T expanders (≥45.2 CAR T-

SUBMITTER: Garcia de la Torre I 

PROVIDER: S-EPMC12841578 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature